Four factors recorded at diagnosis identify men with low-volume de novo metastatic hormone- sensitive prostate cancer whose survival is worse than high-volume disease
This study of over 16,000 men with de novo metastatic hormone-sensitive prostate cancer identifies four specific diagnostic factors (age ≥80, PSA ≥100 ng/mL, liver/brain metastasis, and Gleason score ≥9) that pinpoint a subset of low-volume patients with survival outcomes worse than those with high-volume disease, yet who are currently the least likely to receive chemotherapy.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
Prostate cancer is a common disease in men, and when it spreads beyond the prostate gland to other parts of the body, it becomes a serious, life-threatening condition. Doctors have long known that the amount of cancer present at the time of diagnosis matters greatly for a patient's future. They categorize this spread into "low-volume" and "high-volume" disease. Generally, high-volume disease, which involves many spots of cancer or spread to vital organs like the liver, is considered more dangerous and often receives more aggressive treatment. Low-volume disease, which is limited to the bones or lymph nodes, has traditionally been viewed as less severe. However, this broad categorization has a blind spot: some men with what is called low-volume disease still die very quickly, while the current system fails to identify them early enough to offer the strongest possible care.
A team of researchers from Yokohama City University in Japan set out to fix this gap by looking at a massive database of medical records. They analyzed the histories of over 16,000 men who were diagnosed with metastatic prostate cancer for the first time between 2018 and 2023. The researchers were not looking for a new drug or a new type of surgery; instead, they wanted to see if simple facts already recorded at the moment of diagnosis could predict which men were at the highest risk of dying soon, even if their cancer appeared to be low-volume. They examined every detail available in the records, including the patient's age, the level of a specific protein in the blood called PSA, the location of the cancer spread, and the microscopic appearance of the tumor cells.
The study revealed that four specific factors, when present together, act as a powerful warning sign. These factors are: being 80 years of age or older, having a blood PSA level of 100 nanograms per milliliter or higher, having cancer that has spread to the liver or the brain, and having a tumor cell grade of 9 or higher on a standard scale. The researchers found that these four clues are independent of one another, meaning each one adds its own weight to the risk. When they counted how many of these factors a man had, a clear pattern emerged. The more factors present, the shorter the survival time. For every additional factor a man had, his risk of death increased significantly.
The most striking discovery concerned the men who did not have cancer in their vital organs, a group that includes all patients with low-volume disease. Within this group, the researchers identified a small but critical subset of men who had three of the four risk factors. These men were all 80 years or older, had very high PSA levels, and had high-grade tumors. Despite having no cancer in their liver or brain, their survival was actually worse than that of men with high-volume disease who had cancer in their vital organs. The median survival for this specific group of 758 men was just 25.7 months, compared to 33.9 months for the high-volume group. In other words, these men were dying faster than those with the most extensive spread of cancer, yet the current medical guidelines did not flag them as high-risk.
This finding highlights a troubling gap in current treatment practices. The study showed that while men with high-volume disease received chemotherapy in about 32 percent of cases, this specific group of high-risk, low-volume men received it in only 5.7 percent of cases. The researchers noted that age played a complex role; while being 80 or older was a strong predictor of a shorter life, it also seemed to make doctors less likely to prescribe aggressive chemotherapy, perhaps due to concerns about tolerance. The data suggests that these older men are being denied the intensive treatment that might help them, simply because their disease volume is classified as "low" and they do not fit the traditional profile of a high-risk patient.
The authors are careful to state that their work identifies a group of men who are at high risk of early death, but it does not prove that giving them more aggressive treatment will save them. The database they used did not contain detailed records of every drug given, so they could not measure the benefit of specific therapies for this group. However, the study makes a compelling case that the current system of classifying prostate cancer by volume alone is too blunt an instrument. It misses a specific type of patient who looks like a low-risk candidate on paper but behaves like a high-risk one in reality. By using these four simple factors recorded at diagnosis, doctors could potentially identify these men earlier and consider whether they might benefit from the more intensive treatment strategies that are currently reserved for those with more obvious, widespread disease.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.